Mode
Text Size
Log in / Sign up
N/A N=5,946 Health Services Research

Engaging Patients to Promote Deprescribing

Medical Overuse · Inappropriate Prescribing · Deprescriptions

Enrolled (actual)
5,946
Serious AEs
1.0%
Results posted
May 2025
Primary outcome: Primary: Deprescribing — 748; 653 Participants — p=0.008

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Direct to patient medication brochure (Behavioral)
Age
Pediatric, Adult, Older Adult
Sex
All
Sponsor
VA Office of Research and Development
Primary completion
Oct 2023

Outcome Measures

OutcomeResultp-value
PRIMARY
Deprescribing
748; 653 0.008 sig
SECONDARY
Deprescribing Conversations
12; 37; 353

Summary

One mechanism to reduce potentially inappropriate medications is through deprescribing, a deimplementation-based approach to thoughtfully discontinue a medication a patient is currently prescribed. Many interventions to overcome deprescribing barriers target the provider, who is already overburdened. Although some believe providers have primary responsibility for deprescribing, patient-initiated discontinuation discussions can effectively facilitate deprescribing. In a single-site pilot study, the investigators successfully engaged VA Primary Care patients to facilitate deprescribing of select potentially inappropriate medications. The investigators now propose a multisite randomized controlled trial of engaging Veterans who may be deprescribing candidates. By study end, the investigators will have established the effectiveness of an innovative, low-tech, patient-focused intervention to promote deprescribing, thereby directly improving quality, safety, and value of VA care while also setting the stage for generalization of this approach to other potentially inappropriate medications.

Eligibility Criteria

Inclusion Criteria

  • Veteran with a Primary Care appointment at one of three Veteran Affairs Medical Centers (including Community Based Outpatient Clinics)
  • PPI Cohort:
  • >90 consecutive days of PPI at any dose
  • Diabetes Cohorts:
  • HbA1c 65 years
  • Renal impairment
  • Cognitive impairment
  • either >90 consecutive days insulin or sulfonylurea or >90 consecutive days of >2 DM medications (neither of which is insulin or sulfonylurea)
  • Gaba Cohort:
  • >90 consecutive days with total daily dose >1800mg

Exclusion Criteria

  • PPI Cohort Exclusions:
  • Diagnosis warranting PPI treatment
  • Medication warranting PPI treatment
  • Gaba Cohort Exclusions:
  • Neuropathic pain
  • Seizure disorder
  • and/or Cancer-related pain
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT04294901). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search